01898nam a2200409 i 4500001001300000003000300013005001700016008004100033040003000074042000800104043001200112050001500124074000900139086002000148088002200168110004300190240003600233245022000269264007000489300002400559336002600583337002800609338002700637500003600664500003300700500002200733500002500755500002500780650005500805650006200860650008400922650004201006650005301048650005401101655003101155776030201186on1015373866BD20180227124719.0171215s2017    dcu      l   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  aKF50b.U56  a05750 aAE 2.110:115-52  aPublic Law 115-521 aUnited States,eenacting jurisdiction.10aFDA Reauthorization Act of 201713aAn Act to Amend the Federal Food, Drug, and Cosmetic Act to Revise and Extend the User-Fee Programs for Prescription Drugs, Medical Devices, Generic Drugs, and Biosimilar Biological Products, and for Other Purposes. 1a[Washington, D.C.] :b[U.S. Government Publishing Office],c2017.  a[86] pages ;c24 cm  atextbtxt2rdacontent  aunmediatedbn2rdamedia  avolumebnc2rdacarrier  aShipping list no.: 2018-0084-P.  a"Aug. 18, 2017 (H.R. 2430)."  a"131 Stat. 1005."  a"Public Law 115-52."  aCRDP Program record. 0aDrugsxPricesxLaw and legislationzUnited States. 0aPrescription pricingxLaw and legislationzUnited States. 0aMedical instruments and apparatus industryxLaw and legislationzUnited States. 0aGeneric drugsxPriceszUnited States. 0aBiologicalsxLaw and legislationzUnited States. 0aUser chargesxLaw and legislationzUnited States. 7aStatutes and codes.2lcgft08iOnline version:aUnited States.sFDA Reauthorization Act of 2017.tAct to Amend the Federal Food, Drug, and Cosmetic Act to Revise and Extend the User-Fee Programs for Prescription Drugs, Medical Devices, Generic Drugs, and Biosimilar Biological Products, and for Other Purposesw(OCoLC)1015373781